AstraZeneca's recent FDA rejection of a subcutaneous formulation for its lupus treatment Saphnelo has led to share price declines, overshadowing strong debut trading on the New York Stock Exchange and promising earnings projections. Despite these challenges, the company is bolstering its oncology portfolio with the FDA's priority review of DATROWAY, alongside a commitment to invest $50 billion by 2030 to enhance its U.S. market presence. Positive revenue growth and strategic collaborations position AstraZeneca for substantial long-term growth, despite current operational hurdles.
“The US FDA rejects a version of AstraZeneca's lupus medicine that would make it easier to administer.”
“.@POTUS on slashing drug prices: "AstraZeneca's slashing the price of a common inhaler from $458 to $51 — a difference of nearly 800%."”
“Shares of AstraZeneca, the UK’s biggest drugmaker, will start trading on the New York Stock Exchange following a listing upgrade.”
“Trump has secured deals with several major drugmakers to offer medicines at discounted prices. The five companies include AstraZeneca PLC (NYSE:AZN), Eli Lilly And Co. (NYSE:LLY), EMD Serono, Novo Nordisk (NYSE:NVO), and Pfizer Inc.(NYSE:PFE).”
“Initially, discounts are available for 43 drugs from five drugmakers: AstraZeneca (AZN), Eli Lilly (LLY), EMD Serono, Novo Nordisk (NVO), and Pfizer (PFE).”
“Wall Street analysts expect Astrazeneca (AZN) to post quarterly earnings of $2.18 per share in its upcoming report, which indicates a year-over-year increase of 3.8%.”
“Revenues are expected to be $15.78 billion, up 6% from the year-ago quarter.”
“The DURIPANC study is an investigator-initiated, exploratory, open-label, single-center study expected to enroll up to 25 subjects in the Phase 2 portion. The clinical trial is a joint collaboration between AIM, AstraZeneca and Erasmus Medical Center (“Erasmus MC”) in the Netherlands.”
“The primary objective of the study is the clinical benefit rate of the combination therapy.”
“Erasmus MC expects that detailed data will be published later this year.”
“AstraZeneca AZN is scheduled to report fourth-quarter and full-year 2025 results on Feb. 10, before the opening bell. In the last reported quarter, the company delivered an earnings surprise of 4.39%.”
“Sales of AstraZeneca’s key medicines, mainly cancer drugs — Calquence, Lynparza, Tagrisso and Imfinzi — and diabetes medicine Farxiga/Forxiga are expected to have driven the company’s fourth-quarter sales, backed by strong demand trends.”